BidaskClub upgraded shares of Opko Health, Inc. (NASDAQ:OPK) from a sell rating to a hold rating in a research report report published on Monday, July 24th.
Several other equities research analysts also recently commented on the company. Zacks Investment Research raised Opko Health from a hold rating to a buy rating and set a $7.25 price objective for the company in a report on Friday, July 21st. Barrington Research increased their price target on Opko Health to $11.00 and gave the company an outperform rating in a research note on Tuesday, July 18th. Ladenburg Thalmann Financial Services restated a buy rating and issued a $19.50 price target on shares of Opko Health in a research note on Friday, June 16th. Finally, Jefferies Group LLC restated a hold rating and issued a $8.00 price target on shares of Opko Health in a research note on Monday, June 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. Opko Health presently has an average rating of Hold and an average target price of $14.61.
Opko Health (OPK) opened at 6.24 on Monday. Opko Health has a 1-year low of $5.99 and a 1-year high of $12.15. The company’s market capitalization is $3.49 billion. The firm’s 50-day moving average is $6.38 and its 200-day moving average is $7.28.
Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. The company had revenue of $314.20 million during the quarter, compared to the consensus estimate of $322.64 million. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The firm’s revenue for the quarter was down 12.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.02 EPS. Equities research analysts predict that Opko Health will post ($0.20) EPS for the current year.
WARNING: This piece of content was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.com-unik.info/2017/08/12/opko-health-inc-nasdaqopk-upgraded-to-hold-by-bidaskclub-updated-updated.html.
In related news, Director Richard A. Lerner acquired 10,000 shares of the stock in a transaction dated Monday, June 5th. The stock was bought at an average cost of $6.31 per share, for a total transaction of $63,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Phillip Md Et Al Frost acquired 207,700 shares of the stock in a transaction dated Wednesday, May 31st. The shares were bought at an average price of $6.11 per share, with a total value of $1,269,047.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $18,751,290.61. The disclosure for this purchase can be found here. Insiders purchased 1,631,000 shares of company stock worth $10,394,917 over the last ninety days. 40.19% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of the company. AQR Capital Management LLC acquired a new stake in shares of Opko Health during the fourth quarter worth $105,000. Comerica Bank acquired a new stake in shares of Opko Health during the fourth quarter worth $117,000. Timber Hill LLC acquired a new stake in shares of Opko Health during the first quarter worth $114,000. World Asset Management Inc increased its stake in shares of Opko Health by 23.6% in the first quarter. World Asset Management Inc now owns 15,176 shares of the biotechnology company’s stock worth $121,000 after buying an additional 2,900 shares during the last quarter. Finally, IFC Holdings Incorporated FL increased its stake in shares of Opko Health by 15.9% in the first quarter. IFC Holdings Incorporated FL now owns 15,339 shares of the biotechnology company’s stock worth $122,000 after buying an additional 2,100 shares during the last quarter. Institutional investors and hedge funds own 23.05% of the company’s stock.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
What are top analysts saying about Opko Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Opko Health Inc. and related companies.